MX2023013227A - Regimen de dosis para terapia combinada dirigida a dll3 y pd-1. - Google Patents

Regimen de dosis para terapia combinada dirigida a dll3 y pd-1.

Info

Publication number
MX2023013227A
MX2023013227A MX2023013227A MX2023013227A MX2023013227A MX 2023013227 A MX2023013227 A MX 2023013227A MX 2023013227 A MX2023013227 A MX 2023013227A MX 2023013227 A MX2023013227 A MX 2023013227A MX 2023013227 A MX2023013227 A MX 2023013227A
Authority
MX
Mexico
Prior art keywords
combination therapy
dosing regimen
dll3
therapy targeting
targeting dll3
Prior art date
Application number
MX2023013227A
Other languages
English (en)
Spanish (es)
Inventor
Mukul Minocha
Aditya Shetty
Nooshin Hashemi Sadraei
Marie - Ann Damiette SMIT
Hansen Wong
Siddhartha Roychoudhury
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023013227A publication Critical patent/MX2023013227A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023013227A 2021-05-10 2022-05-06 Regimen de dosis para terapia combinada dirigida a dll3 y pd-1. MX2023013227A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163186569P 2021-05-10 2021-05-10
PCT/US2022/028135 WO2022240688A1 (en) 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting dll3 and pd-1

Publications (1)

Publication Number Publication Date
MX2023013227A true MX2023013227A (es) 2024-01-29

Family

ID=84029376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013227A MX2023013227A (es) 2021-05-10 2022-05-06 Regimen de dosis para terapia combinada dirigida a dll3 y pd-1.

Country Status (12)

Country Link
US (1) US20240317856A1 (enExample)
EP (1) EP4337252A4 (enExample)
JP (1) JP2024518947A (enExample)
KR (1) KR20240006585A (enExample)
CN (1) CN117377488A (enExample)
AU (1) AU2022273509A1 (enExample)
CA (1) CA3217141A1 (enExample)
CL (1) CL2023003357A1 (enExample)
IL (1) IL307646A (enExample)
MX (1) MX2023013227A (enExample)
TW (1) TW202309092A (enExample)
WO (1) WO2022240688A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
KR20240153575A (ko) * 2022-02-23 2024-10-23 암젠 인크 Dll3을 표적화하는 암 치료
WO2024123965A2 (en) * 2022-12-08 2024-06-13 Amgen Inc. Methods for treating dll3-expressing cancer
EP4712977A1 (en) * 2023-05-19 2026-03-25 Boehringer Ingelheim International GmbH Uses of t cell engaging proteins in the treatment of cancer
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
JP7479290B2 (ja) * 2018-04-10 2024-05-08 アムジエン・インコーポレーテツド Ｄｌｌ３に対するキメラ受容体及びその使用方法
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
AU2022273509A1 (en) 2023-10-19
US20240317856A1 (en) 2024-09-26
CN117377488A (zh) 2024-01-09
JP2024518947A (ja) 2024-05-08
EP4337252A4 (en) 2025-04-23
KR20240006585A (ko) 2024-01-15
TW202309092A (zh) 2023-03-01
EP4337252A1 (en) 2024-03-20
CA3217141A1 (en) 2022-11-17
WO2022240688A1 (en) 2022-11-17
CL2023003357A1 (es) 2024-06-07
IL307646A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
MX2023013227A (es) Regimen de dosis para terapia combinada dirigida a dll3 y pd-1.
Chen et al. Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
JOP20240188A1 (ar) معالجة سرطان تستهدف dll3
CL2020002945A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
TN2022000113A1 (en) Dosing regimen for anti-dll3 agents
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
ZA201907225B (en) Treatment of her2 positive cancers
ZA202202363B (en) Antibodies against ilt2 and use thereof
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
WO2022010813A3 (en) Enhancing immune responses through targeted antigen expression
MX2023008285A (es) Conjugado de anticuerpo anti-dll3-farmaco.
JOP20230243A1 (ar) طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد
MX2025007211A (es) Anticuerpo anti-cm bxet, conjugado anticuerpo-farmaco y metodo de preparacion de estos y uso de estos
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
MX2022014886A (es) Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
MX2022006786A (es) Método de tratamiento de cáncer mediante la administración de un agente terapéutico anti-pd-1 o anti-pd-l1 mediante un dispositivo de administración linfática.
JOP20230112A1 (ar) أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
CL2025002930A1 (es) Programa de dosificación de un inhibidor de her.2
MX2023006404A (es) Terapia combinada de anticuerpos y taxanos.
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
JOP20240049A1 (ar) سوتوراسيب وجسم مضاد لـ egfr لعلاج سرطان يشمل طفرة kras g12c